Larimar Therapeutics, Inc. LRMR
2.32 USD -0.44 (-15.94%)
At closeNov 5, 2026, 6:12 PM EST
2.32 0.00 -0.02%
After hours · Nov 5, 6:12 PM ET
2.27 Day range 2.83
1.92 52-week range 6.42
- YTD
- -39.11%
- 1 year
- -27.95%
- Market cap
- 241.01M
- EPS (ttm)
- -1.66
- Shares out
- 63.81M
- Forward P/E
- -2.57
- YTD return
- -39.11%
- 1-year return
- -27.95%
- Volume
- 1.77M
- Avg volume
- 1.31M
- Open
- 2.76
- Previous close
- 2.76
- Day's range
- 2.27 – 2.83
- 52-week range
- 1.92 – 6.42
- Beta
- 0.71
- Analysts
- Strong Buy
- Price target
- 20.41 (+779.7%)
5D -0.32 (-12.12%)
Key statistics
- Enterprise value
- 57.52M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -35.22M
- Total cash
- 203.71M
- Total debt
- 5.36M
- Return on equity
- -44.50%
- Short % of float
- 9.31%
- 50-day average
- 6.92
- 200-day average
- 7.61
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 20.41 +779.7% upside
Now 2.32
- Target (low)
- 12.49
- Target (mean)
- 20.41
- Target (high)
- 36.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy2
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.32491.
Financials — quick view
LRMR Revenue — quarterly 0
LRMR Net income — quarterly -32.78M
LRMR EPS — quarterly 0.30
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2024 | Sep 1, 2024 | -0.37 | -0.24 | +0.13 | +35.14% |
| Aug 7, 2024 | Jun 1, 2024 | -0.32 | -0.34 | -0.02 | -6.25% |
| May 9, 2024 | Mar 1, 2024 | -0.24 | -0.27 | -0.03 | -12.50% |
| Mar 14, 2024 | Dec 1, 2023 | -0.25 | -0.30 | -0.05 | -20.00% |
| Nov 14, 2023 | Sep 1, 2023 | -0.23 | -0.21 | +0.02 | +8.70% |
| Aug 10, 2023 | Jun 1, 2023 | -0.21 | -0.19 | +0.02 | +9.52% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2024 | Oppenheimer | init | — | Outperform |
| Oct 3, 2024 | Wedbush | init | — | Outperform |
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- larimartx.com
News
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference 
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead 
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner 
Larimar Therapeutics Appoints John Harlow As President and COO, Effective September 29 
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer 
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery 
BlackRock Inc. Buys New Position in Larimar Therapeutics, Inc. $LRMR 
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages 
Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR 
Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
Your note
Sign in to keep a note on LRMR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEN MAIMON CAROLE S | Chief Executive Officer | Stock Award(Grant) | Jan 16, 2024 | 332,954 |
| CELANO MICHAEL | Chief Financial Officer | Stock Award(Grant) | Jan 16, 2024 | 143,996 |
| CLAYTON RUSSELL | Officer | Stock Award(Grant) | Jan 16, 2024 | 22,500 |
| FLYNN JAMES E | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 15, 2024 | 0 |
| HAMILTON THOMAS EDWARD | Director | Purchase | Feb 15, 2024 | 724,231 |
| SHANKAR GOPI | Officer | Stock Award(Grant) | Jan 16, 2024 | 27,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 33.28% | 21,231,974 | 84.08M | Sep 29, 2024 |
| RA Capital Management, L.P. | 9.47% | 6,045,351 | 23.94M | Sep 29, 2024 |
| Janus Henderson Group PLC | 8.72% | 5,566,855 | 22.04M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 6.66% | 4,249,491 | 16.83M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 6.53% | 4,166,829 | 16.50M | Sep 29, 2024 |
| Blackrock Inc. | 4.66% | 2,972,953 | 11.77M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.10% | 1,341,890 | 5.31M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.72% | 1,095,985 | 4.34M | Oct 30, 2024 |
| Fidelity Advisor Biotechnology Fund | 0.82% | 524,800 | 2.08M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 510,244 | 2.02M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.68% | 431,074 | 1.71M | Aug 30, 2024 |
| Alger Fund-Small Cap Growth Fund | 0.63% | 398,960 | 1.58M | Jul 30, 2024 |